Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival...

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology...

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )

ASCO 2026: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2026: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression...

Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive metastatic triple-negative breas ( Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA )

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk...

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia...

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma ( Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA )

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant...

Dr Vincent Chung - City of Hope, Duarte, USA

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer ( Dr Vincent Chung - City of Hope, Duarte, USA )

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R...

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in...

Dr Georg Lenz - University Hospital Münster, Münster, Germany

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas ( Dr Georg Lenz - University Hospital Münster, Münster, Germany )

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard...

Dr Hope Rugo - City of Hope, Duarte, USA

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable...

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma ( Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China )

More from ecancer